Phase II Open-Label Safety Extension Study Of Tanezumab In Cancer Patients With Pain Due To Bone Metastases [EXTENSION OF 700027920]
Phase of Trial: Phase II
Latest Information Update: 24 Aug 2016
At a glance
- Drugs Tanezumab (Primary)
- Indications Cancer pain
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Pfizer
- 04 May 2013 Planned number of patients changed from 58 to 60 as reported by European Clinical Trials Database.
- 04 May 2013 New source identified and integrated (European Clinical Trials Database record: EudraCT2008-005182-66).
- 05 Mar 2013 New trial record